STAT3 Gene Function
Signal Transducer and Activator of Transcription 3
Overview
STAT3 is a transcription factor activated by cytokines and growth factors via JAK kinases. It drives expression of survival, proliferation, and angiogenesis genes and is constitutively active in many hematologic and solid tumors.
Molecular Mechanism
Mechanism Summary
Cytokine/growth factor receptor-associated JAK kinases phosphorylate STAT3 at Tyr705, enabling SH2-domain-mediated dimerisation. STAT3 dimers translocate to the nucleus and bind GAS elements, transcribing BCL-XL, MCL1, cyclin D1, VEGFA, and immunosuppressive IL-10.
Step-by-Step Mechanism
IL-6 (or related cytokines: IL-10, IL-11, oncostatin M) binds gp130 receptor, inducing homodimerisation or heterodimerisation of gp130, which activates constitutively associated JAK1 and JAK2 kinases through trans-autophosphorylation.
JAK1/JAK2 phosphorylate STAT3 at Tyr705. This creates an SH2-binding motif that enables two STAT3 monomers to form a reciprocal SH2-pTyr705 dimer — the transcriptionally active form.
STAT3 dimers undergo importin-α3/α6-mediated nuclear translocation and bind GAS (gamma-activated sequence: TTCN2-4GAA) elements in target gene promoters, recruiting CBP/p300 co-activators.
STAT3 also transcribes immunosuppressive genes (IL-10, TGF-β, PD-L1), creating a tumour microenvironment that suppresses cytotoxic T-cell and NK cell function. This positions STAT3 as a key driver of immune evasion.
Negative regulation by SOCS3 (itself a STAT3 target gene — another negative feedback loop): SOCS3 binds JAK2 and gp130, blocking further STAT3 phosphorylation. SOCS3 is epigenetically silenced in many malignancies, sustaining constitutive STAT3.
Upstream Regulators
Trans-autophosphorylate and phosphorylate STAT3 Tyr705 upon cytokine receptor activation
Directly phosphorylate STAT3 Tyr705 downstream of oncogenic fusions (BCR-ABL, EML4-ALK)
STAT3-induced feedback inhibitor; silenced by promoter methylation in cancer
Downstream Targets
Anti-apoptotic programme; chemotherapy resistance
Proliferative drive
Angiogenesis; invasion; metastasis
Immunosuppressive tumour microenvironment
Key Post-Translational Modifications
SH2-domain dimerisation; nuclear translocation; transcriptional activation
Enhances transcriptional activity; mitochondrial STAT3 localisation
Promotes STAT3 dimerisation and DNA binding independent of Tyr705
Disease Mechanism
Constitutive STAT3 is found in ~70% of haematological malignancies, hepatocellular carcinoma, and NSCLC. STAT3-activating JAK2 V617F is the founding driver mutation in myeloproliferative neoplasms (polycythaemia vera, essential thrombocythaemia). JAK1/JAK2 inhibitors (ruxolitinib) are approved for myelofibrosis and polycythaemia vera. Direct STAT3 SH2 inhibitors are in early-phase clinical trials.
Database References
Key Pathways
- ·JAK-STAT signaling
- ·Cytokine signaling
- ·IL-6 signaling
- ·Immune evasion
Disease Associations
- ·Lymphoma
- ·Multiple myeloma
- ·Hepatocellular carcinoma
- ·Lung cancer
Research Activity
STAT3 is an actively studied target: about 20+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track STAT3 trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About STAT3
What does STAT3 do in cancer?
Constitutively activated STAT3 (typically phosphorylated at Y705 by JAK kinases) drives expression of anti-apoptotic proteins (BCL-XL, MCL1), proliferation genes (cyclin D1), and immunosuppressive cytokines (IL-10, TGF-β). This dual role — promoting tumour cell survival and suppressing anti-tumour immunity — makes STAT3 a central oncogenic hub.
How is STAT3 abnormally activated in cancer?
STAT3 is constitutively activated by upstream IL-6 receptor/JAK2 signalling in ~70% of haematological malignancies, by oncogenic fusions (EML4-ALK, BCR-ABL), and by activating JAK1/JAK2/STAT3 mutations in T-cell lymphomas. Autocrine cytokine loops and loss of negative regulators (SOCS proteins) also maintain constitutive activation.
Are there drugs that target STAT3?
JAK inhibitors (ruxolitinib, tofacitinib) suppress upstream JAK-STAT3 signalling and are approved in myeloproliferative neoplasms and inflammatory disorders. Direct STAT3 inhibitors targeting the SH2 domain are in early clinical development. The large protein-protein interaction surface of STAT3 has historically made direct inhibition difficult.